Want to get a preview about how you can gain crucial information from Technavio’s market research report? Check out the latest facts about the peanut allergy therapeutics industry
The global peanut allergy therapeutics market is expected to grow at a colossal CAGR of almost 90% during the forecast period
Peanut allergy industry growth is expected to grow at a mammoth rate over the next five years driven by the increase in collaborations for R&D. Drug development and marketing is an expensive and lengthy affair in the pharmaceutical industry as the peanut allergy therapy companies need extensive funding, advanced manufacturing units, and a strong distribution network. Several peanut allergy therapy companies are engaging in collaborations to gain a strong foothold on funds and skill set to develop novel peanut allergy treatment methods. Another factor behind the rapid growth of the global peanut allergy market is the growing prevalence of various types of food allergy, including peanut allergy in many developed countries. Technavio’s peanut allergy industry analysis reveals promising markets around the world.
Get a free sample of this report now!
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.
Americas will drive the largest incremental growth for peanut allergy therapeutics market
The Americas will drive almost 47% of the growth for the global peanut allergy market, while EMEA and APAC are also predicted to make sizeable contributions to the incremental growth in the forecast period. Towards the end of 2018, the Americas dominated the global peanut allergy market with a market share of over 47%, followed by EMEA and APAC. In addition, the Americas are expected to retain their dominant market position through the period of forecast, while, APAC is anticipated to display the fastest rate of growth in comparison to EMEA and the Americas over the next five years.
Aimmune Therapeutics, Aravax, and DBV Technologies are among the leading peanut allergy therapy companies
The global peanut allergy market is forecasted to grow marginally less concentrated over the next five years owing to the presence of a few peanut allergy therapy companies that offer products such as peanut protein and vaccines. Some of the leading peanut allergy therapy companies are conducting extensive R&D on developing drugs and using peanut protein as immunotherapy for peanut allergy. Many international and regional vendors are vying for their share of the peanut allergy market, and players must differentiate themselves to gain vital traction over their peers.
This report offers a complete analysis of several companies, including:
- Aimmune Therapeutics
- Aravax
- DBV Technologies
- HAL Allergy
- Immunomic Therapeutics
We can help! Our analysts can customize this report to meet your requirements. Get in touch